The global ophthalmic pharmaceuticals market consists of medications that are used for the treatment of eye diseases and eye disorders. Ophthalmic drugs play a crucial role in treating several eye conditions such as dry eyes, glaucoma, infection, inflammation, retinal disorders and allergies. These medications are available in various formulations including solutions, creams, gels, ointments and others. Factors such as the rising prevalence of eye diseases, growing geriatric population, increasing investment in R&D and new product launches are fueling the demand for ophthalmic pharmaceuticals.
The ophthalmoplegia market is estimated to be valued at USD 510 Mn in 2024 and is expected to reach USD 850 Mn by 2031, growing at a compound annual growth rate (CAGR) of 7.5% from 2024 to 2031.
Key players operating in the ophthalmic pharmaceuticals market are Novartis AG, Allergan, Bausch Health, Santen Pharmaceutical, Regeneron Pharmaceuticals and EYENEX.
The Global Ophthalmoplegia Market provides several growth opportunities in the form of rising disposable incomes in emerging economies, increasing number of patients suffering from diabetic retinopathy and better access to healthcare facilities globally.
Major companies are expanding their operations globally with focus on Asia Pacific and Latin American regions owing to high prevalence of eye disorders and growing medical tourism.
Market drivers
The demand for ophthalmic pharmaceuticals is primarily driven by the rising geriatric population globally which is more susceptible to developing age-related ophthalmic conditions like cataract, glaucoma and diabetic retinopathy. It is estimated that the number of people aged 65 years and above will reach 1.5 billion by 2050. Growing prevalence of lifestyle diseases such as diabetes is also increasing the risk of developing eye disorders thus propelling the market growth. Introduction of innovative drug delivery systems ensuring better bioavailability and patient compliance acts as a key growth driver.
PEST Analysis
Political: The regulations on healthcare expenditure and standards of care can impact the Ophthalmoplegia market. Regulations need to ensure quality care while also enabling cost effective solutions.
Economic: Factors such as rising income levels, increased healthcare spending and growing insurance coverage positively influence the Ophthalmoplegia market growth. The market is sensitive to changes in the economic condition of key regions.
Social: Growing aging population and increased awareness about eye care leads to higher demand for Ophthalmoplegia treatments. Changing lifestyles and increased screen time also impact the occurrence of eye diseases.
Technological: Advancements in Ophthalmoplegia treatments technologies such as lasers, miniaturization and digital devices are helping treat more patients easily and effectively. Technologies are making treatment affordable and widening access in rural regions also.
The geographical regions where the Ophthalmoplegia market is concentrated in terms of value currently include North America and Western Europe. This is because of high healthcare spending, advanced healthcare infrastructure, and early adoption of new technologies in these regions.
Asia Pacific region is witnessing the fastest growth for the Ophthalmoplegia market led by China and India mainly. Factors fueling growth include rising middle class population, increasing disposable incomes, growing medical tourism, and initiatives by governments to widen health insurance coverage in the region.
Get this Report in Japanese Language: 世界の眼筋麻痺市場
Get this Report in Korean Language: 글로벌 안구운동마비 시장
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)
